Literature DB >> 24282051

Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis.

Ji Yong Ahn1, Kyung Hun Lee, Chang Hwan Choi, Ju Wan Kim, Hyun Woong Lee, Jeong Wook Kim, Mi Kyung Kim, Gui Young Kwon, Seungbong Han, Seong-Eun Kim, Sung Min Kim, Sae Kyung Chang.   

Abstract

BACKGROUND AND AIM: Mucosal immune activity may participate in irritable bowel syndrome (IBS) pathogenesis. Mast- and T cell numbers from patients with IBS or ulcerative colitis (UC) and healthy controls were determined.
METHODS: Between November 2007 and May 2012, patients with diarrhea-predominant IBS (D-IBS, n = 83), 49 patients with UC, and 25 healthy controls were recruited. Of the UC group, 28 were in remission and 21 had mildly active UC. Biopsies from each colon segment were subjected to immunohistochemical analysis. The mast cells, intraepithelial lymphocytes (IELs), and lamina proprial lymphocytes (LPLs) were counted.
RESULTS: Compared to the healthy controls, the patients with D-IBS, UC in remission, and mildly active UC had significantly higher mean colorectal mucosal mast-cell, IEL, and LPL counts. Comparison with the colon segments (ascending, transverse, descending, and sigmoid segments) that had once been involved in UC (in the patients with remission) revealed that the D-IBS colons had similar immune-cell counts. However, they had significantly fewer immune cells than the colon segments that presently showed involvement in the patients with mildly-activated UC. The mast-cell and IEL counts were similar in the D-IBS rectums and once-involved UC rectums but significantly higher in the presently-involved UC rectums. However, both the once-involved and presently-involved UC rectums had significantly higher LPL counts than the D-IBS rectums.
CONCLUSIONS: Patients with D-IBS had significantly higher colonic mucosal immune-cell counts than healthy controls but had similar counts to patients with UC in remission. The symptoms in both conditions may originate from low-grade inflammation in the colonic mucosa.

Entities:  

Mesh:

Year:  2013        PMID: 24282051     DOI: 10.1007/s10620-013-2930-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  48 in total

1.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

2.  A quantitative immunohistochemical evaluation of inflammatory cells at the affected and unaffected sites of inflammatory bowel disease.

Authors:  K Yamagata; M Tanaka; H Kudo
Journal:  J Gastroenterol Hepatol       Date:  1998-08       Impact factor: 4.029

3.  [Increase of intraepithelial lymphocytes in patients with irritable bowel syndrome].

Authors:  F Arévalo; V Aragon; P Montes; E Guzmán; E Monge
Journal:  Rev Gastroenterol Peru       Date:  2011 Oct-Dec

4.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

5.  Quality of life in persons with irritable bowel syndrome: development and validation of a new measure.

Authors:  D L Patrick; D A Drossman; I O Frederick; J DiCesare; K L Puder
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

6.  Role for protease activity in visceral pain in irritable bowel syndrome.

Authors:  Nicolas Cenac; Christopher N Andrews; Marinella Holzhausen; Kevin Chapman; Graeme Cottrell; Patricia Andrade-Gordon; Martin Steinhoff; Giovanni Barbara; Paul Beck; Nigel W Bunnett; Keith A Sharkey; Jose Geraldo P Ferraz; Eldon Shaffer; Nathalie Vergnolle
Journal:  J Clin Invest       Date:  2007-02-15       Impact factor: 14.808

7.  Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.

Authors:  Cesare Cremon; Luciana Gargano; Antonio M Morselli-Labate; Donatella Santini; Rosanna F Cogliandro; Roberto De Giorgio; Vincenzo Stanghellini; Roberto Corinaldesi; Giovanni Barbara
Journal:  Am J Gastroenterol       Date:  2009-01-13       Impact factor: 10.864

8.  Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.

Authors:  L-H Wang; X-C Fang; G-Z Pan
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 9.  A role for inflammation in irritable bowel syndrome?

Authors:  G Barbara; R De Giorgio; V Stanghellini; C Cremon; R Corinaldesi
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

10.  The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors.

Authors:  Kwang Jae Lee; Yeong Bae Kim; Jang Hee Kim; Hoek Chun Kwon; Dong Kyu Kim; Sung Won Cho
Journal:  J Gastroenterol Hepatol       Date:  2008-11       Impact factor: 4.029

View more
  20 in total

1.  Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.

Authors:  Olga Bednarska; Susanna A Walter; Maite Casado-Bedmar; Magnus Ström; Eloísa Salvo-Romero; Maria Vicario; Emeran A Mayer; Åsa V Keita
Journal:  Gastroenterology       Date:  2017-07-13       Impact factor: 22.682

Review 2.  IBS and IBD - separate entities or on a spectrum?

Authors:  Robin Spiller; Giles Major
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-26       Impact factor: 46.802

3.  Mast cells in irritable bowel syndrome and ulcerative colitis: function not numbers is what makes all the difference.

Authors:  Theoharis C Theoharides
Journal:  Dig Dis Sci       Date:  2014-01-21       Impact factor: 3.199

Review 4.  Diagnosis and management of functional symptoms in inflammatory bowel disease in remission.

Authors:  Carlos Teruel; Elena Garrido; Francisco Mesonero
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

5.  Altered vasoactive intestinal peptides expression in irritable bowel syndrome patients and rats with trinitrobenzene sulfonic acid-induced colitis.

Authors:  Arseima Y Del Valle-Pinero; LeeAnne B Sherwin; Ethan M Anderson; Robert M Caudle; Wendy A Henderson
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

6.  Comparative Study of the Role of Interepithelial Mucosal Mast Cells in the Context of Intestinal Adenoma-Carcinoma Progression.

Authors:  Tanja Groll; Miguel Silva; Rim Sabrina Jahan Sarker; Markus Tschurtschenthaler; Theresa Schnalzger; Carolin Mogler; Daniela Denk; Sebastian Schölch; Barbara U Schraml; Jürgen Ruland; Roland Rad; Dieter Saur; Wilko Weichert; Moritz Jesinghaus; Kaspar Matiasek; Katja Steiger
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

Review 7.  New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.

Authors:  Amy E Foxx-Orenstein
Journal:  Therap Adv Gastroenterol       Date:  2016-02-21       Impact factor: 4.409

Review 8.  Role of antispasmodics in the treatment of irritable bowel syndrome.

Authors:  Anita Annaházi; Richárd Róka; András Rosztóczy; Tibor Wittmann
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 9.  Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome.

Authors:  William L Hasler; Gintautas Grabauskas; Prashant Singh; Chung Owyang
Journal:  Neurogastroenterol Motil       Date:  2022-03-21       Impact factor: 3.960

Review 10.  Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside.

Authors:  Lei Zhang; Jun Song; Xiaohua Hou
Journal:  J Neurogastroenterol Motil       Date:  2016-04-30       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.